Standard BioTools (LAB) CEO Withholds Shares for Taxes; Ownership Remains 5.68M

Rhea-AI Filing Summary

Michael Egholm, President & CEO and Director of Standard BioTools Inc. (LAB), reported a transaction dated 08/20/2025 in which 54,919 shares of common stock were disposed (Transaction Code F) at $1.27 per share. The filing states these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on May 20, 2024 and March 21, 2025, previously reported on Form 4s. After the withholding, the reporting person beneficially owns 5,681,366 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Egholm.

Positive

• Insider retains substantial ownership: reporting person beneficially owns 5,681,366 shares after the transaction
• Transaction is administrative: shares were withheld to satisfy tax withholding from RSU vesting rather than an open-market sale

Negative

• Reduction in shares held: 54,919 shares were disposed (withheld) at $1.27 per share

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding disposition from RSU vesting; maintains substantial direct ownership.

The reported disposition is classified as Code F, indicating shares were withheld to satisfy tax obligations upon RSU vesting. This is a common administrative transaction and does not reflect an active open-market sale decision by the insider. The filing confirms the source of the withheld shares as two previously granted RSU awards dated May 20, 2024 and March 21, 2025. The insider continues to hold a large direct stake of 5,681,366 shares, which supports continuity of management ownership alignment with shareholders.

Securities/Insider Activity Analyst

TL;DR: Small disposal relative to total holdings; transaction executed for tax withholding at a low per-share price.

The transaction involves 54,919 shares withheld at a reported price of $1.27 per share. Compared to the post-transaction direct beneficial ownership of 5,681,366 shares, the withheld amount represents a minor reduction in holdings. The Form 4 references RSU grants previously reported, linking the disposal to ordinary compensation vesting mechanics rather than an investment exit. No derivative transactions were reported on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Egholm Michael

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		F		54,919(1)	D	$1.27	5,681,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively.

	/s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Michael Egholm report on Form 4 for LAB?

He reported a disposal of 54,919 common shares on 08/20/2025, listed as Code F (withheld to satisfy tax obligations).

Why were the 54,919 LAB shares disposed?

The shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on May 20, 2024 and March 21, 2025.

How many LAB shares does the reporting person own after the transaction?

5,681,366 shares of common stock are beneficially owned following the reported transaction, held directly.

At what price were the withheld LAB shares recorded?

$1.27 per share for the 54,919 shares withheld.

Does this Form 4 report any derivative transactions for LAB by the reporting person?

No derivative securities transactions are reported on this Form 4.